Research Funding

  • July 15, 2009 - June 30, 2014 - The Response of Cancer and Stem/Progenitor Cells to Telomere Disruption , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA134552

Education

Swarthmore College, Swarthmore, PA, BA, 1995, Biology
Duke University, Durham, NC, PhD, 2002, Microbiology
Duke University, Durham, NC, MD, 2003, Medicine
University of California, San Francisco, CA, Resident/Fellow, 2003-2006, Anatomic Pathology
University of California, San Francisco, CA, Postdoctoral Fellow, 2005-2008, Biochemistry

Honors & Awards

  • 1995
    Phi Beta Kappa honor society
  • 1995
    Sigma Xi honor society
  • 1996-2003
    Medical Scientist Training Program Fellowship
  • 2005
    Ruth L. Kirschstein Postdoctoral Fellowship (declined)
  • 2005-2008
    American Cancer Society Postdoctoral Fellowship
  • 2010-present
    Mentored Clinical Scientist Development Award (K08)

Selected Publications

  1. Chan GJ, Stohr BA, Osunkoya AO, Croom NA, Cho SJ, Balassanian R, Charu V, Bean GR, Chan E. Wilms Tumor: An Unexpected Diagnosis in Adult Patients. Arch Pathol Lab Med. 2023 Sep 26.  View on PubMed
  2. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2023 Jul 18.  View on PubMed
  3. Haolong Li, James E. Melnyk, Becky Xu Hua Fu, Siyu Feng, Martin Sjöström, Raunak Shrestha, Meng Zhang, Lisa N. Chesner, Hyun Jin Shin, Marsha Calvert, Jonathan Chou, Rajdeep Das, Emily A. Egusa, Aidan Winters, Jun Zhu, Ashutosh Maheshwari, Junjie T. Hua, Mohammed Alshalalfa, William S. Chen, Bradley A. Stohr, Javed Siddiqui, Bo Huang, Eric J. Small, David A. Quigley, Kevan M. Shokat, Luke A. Gilbert, Felix Y. Feng. Abstract B066: Genome-wide CRISPR screens identify PTGES3 as a druggable AR modulator. Cancer Research. 2023 Jun 2; 83(11_Supplement):b066-b066.  View on PubMed
  4. Warmke LM, Al-Ibraheemi A, Wang L, Parham D, Rudzinski ER, Stohr BA, Miles C, Habeeb O, Davis JL. FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and "NTRK-rearranged" spindle cell neoplasms. Genes Chromosomes Cancer. 2023 Nov; 62(11):641-647.  View on PubMed
  5. Bahceci D, Nguyen JK, Sangoi AR, Stohr BA, Chan E. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells. Hum Pathol. 2023 06; 136:56-62.  View on PubMed
  6. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315.  View on PubMed
  7. Stohr BA, Chan E, Anderson JA, Matoso A, Murati Amador BI, Cheng L, Osunkoya AO. Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study. Hum Pathol. 2022 11; 129:98-102.  View on PubMed
  8. Claire de la Calle, Nancy Greenland, Janet Cowan, Vittorio Fasulo, Martina Maggi, Emily Chan, Bradley Stohr, Jeffry Simko, Katsuto Shinohara, Matthew Cooperberg, Peter Carroll, Hao Nguyen. PD11-12 ASSOCIATIONS OF SERUM-BASED AND URINE-BASED MOLECULAR DIAGNOSTICS WITH HISTOLOGIC SUBTYPING ON PROSTATE BIOPSY. Investigative Urology. 2022 May 1; 207(Supplement 5):e194.  View on PubMed
  9. Sangoi AR, Chan E, Abdulfatah E, Stohr BA, Nguyen J, Trpkov K, Siadat F, Hirsch M, Falzarano S, Udager AM, Kunju LP. p53 null phenotype is a "positive result" in urothelial carcinoma in situ. Mod Pathol. 2022 09; 35(9):1287-1292.  View on PubMed
  10. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706.  View on PubMed
  11. Peng Y, Greenland NY, Lang UE, Stohr BA. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathol Res Pract. 2022 Apr; 232:153831.  View on PubMed
  12. Chan E, Stohr BA, Butler RS, Cox RM, Myles JL, Nguyen JK, Przybycin CG, Reynolds JP, Williamson SR, McKenney JK. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. Am J Surg Pathol. 2022 03 01; 46(3):392-403.  View on PubMed
  13. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718.  View on PubMed
  14. Tanya Jindal, Li Zhang, Jonathan Chou, David Shui, Sima P. Porten, Anthony C. Wong, Emily Chan, Bradley A. Stohr, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Daniel H Kwon, Arpita Desai, Franklin W. Huang, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):531-531.  View on PubMed
  15. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141.  View on PubMed
  16. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33.  View on PubMed
  17. Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2022 01; 119:85-93.  View on PubMed
  18. Heiko Yang, Hanbing Song, Paul Allegakoen, Jamie Xie, Kevin Lu, Bradley Stohr, Maxwell Meng, Sima Porten, Franklin Huang. MP66-08 SINGLE-CELL TRANSCRIPTIONAL PROFILES OF HISTOLOGIC VARIANTS IN BLADDER CANCER. Investigative Urology. 2021 Sep 1; 206(Supplement 3).  View on PubMed
  19. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130.  View on PubMed
  20. Tang S, Meng MV, Slater JB, Gordon JW, Vigneron DB, Stohr BA, Larson PEZ, Wang ZJ. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience. Cancer. 2021 08 01; 127(15):2693-2704.  View on PubMed

Go to UCSF Profiles, powered by CTSI